

Brand Name: Bevespi Aerosphere

Generic: glycopyrrolate/formoterol fumarate

Type: small molecule


Year Accepted/Phase: 2016

Mechanism:


Glycopyrrolate is a muscarinic antagonist that blocks the action of acetylcholine, a neurotransmitter that can cause bronchoconstriction. Formoterol is a long-acting beta2-adrenergic agonist that relaxes the muscles in the airways, making breathing easier.

Chemical Structure:

glycopyrrolate



formoterol



Indication:

Bevespi Aerosphere is indicated for the maintenance treatment of airflow obstruction in patients with Chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Clinical trials:

Clinical Trials for COPD

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/30310273/>

Purpose: Evaluate the efficacy and safety of glycopyrrolate/formoterol fumarate in patients with COPD.

Dates: Clinical trials for Bevespi Aerosphere were conducted in the 2010s.

Results: These trials demonstrated that the combination of glycopyrrolate/formoterol fumarate provided superior bronchodilation compared to either component alone. It also improved lung function, symptoms, and quality of life in patients with COPD.

Impact: The positive results from these trials supported the approval of Bevespi Aerosphere for the maintenance treatment of COPD.